{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T06:50:36Z","timestamp":1794293436679,"version":"4.9.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":1087,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020035","name":"Den A. P. M\u00f8llerske St\u00f8ttefond","doi-asserted-by":"publisher","award":["Grant\/Award Number: 17-L-0002"],"award-info":[{"award-number":["Grant\/Award Number: 17-L-0002"]}],"id":[{"id":"10.13039\/100020035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003491","name":"Herlev Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007405","name":"Hjerteforeningen","doi-asserted-by":"publisher","award":["Grant\/Award Number: 17-R116-A7714-22076; 18-R124-A8573-22107; 21-R150-A9936-22197"],"award-info":[{"award-number":["Grant\/Award Number: 17-R116-A7714-22076; 18-R124-A8573-22107; 21-R150-A9936-22197"]}],"id":[{"id":"10.13039\/100007405","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005275","name":"Region Hovedstaden","doi-asserted-by":"publisher","award":["Grant\/Award Number: A6058"],"award-info":[{"award-number":["Grant\/Award Number: A6058"]}],"id":[{"id":"10.13039\/501100005275","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Research and Innovation Foundation of the Department of Cardiology, Department of Cardiology, Herlev Hospital"},{"DOI":"10.13039\/100020035","name":"Den A. P. M\u00f8llerske St\u00f8ttefond","doi-asserted-by":"publisher","award":["Grant\/Award Number: 17\u2010L\u20100002"],"award-info":[{"award-number":["Grant\/Award Number: 17\u2010L\u20100002"]}],"id":[{"id":"10.13039\/100020035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003491","name":"Herlev Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007405","name":"Hjerteforeningen","doi-asserted-by":"publisher","award":["Grant\/Award Number: 17\u2010R116\u2010A7714\u201022076; 18\u2010R124\u2010A8573\u201022107; 21\u2010R150\u2010A9936\u201022197"],"award-info":[{"award-number":["Grant\/Award Number: 17\u2010R116\u2010A7714\u201022076; 18\u2010R124\u2010A8573\u201022107; 21\u2010R150\u2010A9936\u201022197"]}],"id":[{"id":"10.13039\/100007405","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005275","name":"Region Hovedstaden","doi-asserted-by":"publisher","award":["Grant\/Award Number: A6058"],"award-info":[{"award-number":["Grant\/Award Number: A6058"]}],"id":[{"id":"10.13039\/501100005275","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>It remains unknown whether the consistently observed increase in haematocrit with sodium\u2013glucose cotransporter 2 inhibitors is caused by diuresis-associated haemoconcentration or increased erythropoiesis. We aimed to investigate the early effect of empagliflozin on erythropoiesis and iron metabolism in patients with heart failure with reduced ejection fraction (HFrEF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The Empire HF was a double-blind, randomized, placebo-controlled trial. Patients with a left ventricular ejection fraction (LVEF) \u226440%, New York Heart Association (NYHA) class I\u2013III symptoms, and on stable guideline-directed HFrEF therapy were randomly assigned (1:1) to empagliflozin or matching placebo once daily for 12\u2009weeks. Exploratory outcomes reflecting changes in erythropoiesis and iron metabolism were analysed. In total, 190 patients were randomized. Baseline characteristics were well-balanced between the groups (age: mean 64 [\u00b1\u200911] years; male: 85%; LVEF: mean 29 [\u00b1\u20098)%; NYHA class II: 78%; type 2 diabetes: 13%; anaemia: 28%; chronic kidney disease: 13%). In this post hoc analysis, erythropoietin was increased with empagliflozin compared to placebo from baseline to 12\u2009weeks (adjusted mean difference 2.6 IU\/L, 95% confidence interval [CI] 0.8\u20134.4; p = 0.0046). Moreover, hepcidin was reduced (adjusted ratio of change 0.76, 95% CI 0.59\u20130.97; p = 0.031), with no change observed for erythroferrone (adjusted ratio of change 1.17, 95% CI 0.86\u20131.60; p = 0.31) compared to placebo. No significant treatment-by-subgroup interactions were observed regarding baseline type 2 diabetes, anaemia, or chronic kidney disease (pinteraction\u2009&amp;gt;0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings suggest that empagliflozin increases erythropoiesis and augments early iron utilization in patients with HFrEF. These mechanisms may contribute to the cardioprotective properties of empagliflozin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.2735","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:39:01Z","timestamp":1668472741000},"page":"226-234","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Effects of Empagliflozin on Erythropoiesis in Heart Failure: Data from the Empire HF Trial"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3151-5499","authenticated-orcid":false,"given":"Camilla","family":"Fuchs Andersen","sequence":"first","affiliation":[{"name":"Department of Cardiology, Herlev and Gentofte University Hospital , Herlev ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massar","family":"Omar","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Odense University Hospital , Odense ,","place":["Denmark"]},{"name":"Steno Diabetes Center Odense , Odense ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Glenth\u00f8j","sequence":"additional","affiliation":[{"name":"Department of Haematology, Centre for Cancer and Organ Diseases, Rigshospitalet , Copenhagen ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"El Fassi","sequence":"additional","affiliation":[{"name":"Department of Haematology, Centre for Cancer and Organ Diseases, Rigshospitalet , Copenhagen ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger J.","family":"M\u00f8ller","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Aarhus University Hospital , Aarhus ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Aarhus University , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen A.","family":"Lindholm Kurtzhals","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Centre of Medical Parasitology, Copenhagen University Hospital , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjarne","family":"Styrishave","sequence":"additional","affiliation":[{"name":"Toxicology and Drug Metabolism Group, Department of Pharmacy, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Kistorp","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, University of Copenhagen , Copenhagen ,","place":["Denmark"]},{"name":"Department of Endocrinology, Rigshospitalet , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Tuxen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Bispebjerg and Frederiksberg University Hospital , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael K.","family":"Poulsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Odense University Hospital , Odense ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Faber","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, University of Copenhagen , Copenhagen ,","place":["Denmark"]},{"name":"Department of Internal Medicine, Centre of Endocrinology and Metabolism, Herlev and Gentofte University Hospital , Herlev ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"K\u00f8ber","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, University of Copenhagen , Copenhagen ,","place":["Denmark"]},{"name":"Department of Internal Medicine, Centre of Endocrinology and Metabolism, Herlev and Gentofte University Hospital , Herlev ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Gustafsson","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, University of Copenhagen , Copenhagen ,","place":["Denmark"]},{"name":"Department of Cardiology, Rigshospitalet , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob E.","family":"M\u00f8ller","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Odense University Hospital , Odense ,","place":["Denmark"]},{"name":"Department of Cardiology, Rigshospitalet , Copenhagen ,","place":["Denmark"]},{"name":"Faculty of Health Sciences, University of Southern Denmark , Odense ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Schou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Herlev and Gentofte University Hospital , Herlev ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Jensen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Herlev and Gentofte University Hospital , Herlev ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"key":"2026010913082171200_ejhf2735-bib-0001","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"2026010913082171200_ejhf2735-bib-0002","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/bcpt.13739","article-title":"Sodium-glucose co-transporter-2 inhibitors in heart failure with reduced ejection fraction: current evidence and future perspectives","volume":"131","author":"Jensen","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2026010913082171200_ejhf2735-bib-0003","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026010913082171200_ejhf2735-bib-0004","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026010913082171200_ejhf2735-bib-0005","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure: diuretic and cardiorenal effects","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"key":"2026010913082171200_ejhf2735-bib-0006","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ahj.2020.07.011","article-title":"Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: a double-blinded, randomized, and placebo-controlled trial","volume":"228","author":"Jensen","year":"2020","journal-title":"Am Heart J"},{"key":"2026010913082171200_ejhf2735-bib-0007","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2017","journal-title":"Diabetes Care"},{"key":"2026010913082171200_ejhf2735-bib-0008","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ejhf.2132","article-title":"DAPA-HF Investigators and Committees. Effect of dapagliflozin on anaemia in DAPA-HF","volume":"23","author":"Docherty","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026010913082171200_ejhf2735-bib-0009","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1161\/CIRCULATIONAHA.122.060511","article-title":"DAPA-HF Investigators and Committees. Iron deficiency in heart failure and effect of dapagliflozin: findings from DAPA-HF","volume":"146","author":"Docherty","year":"2022","journal-title":"Circulation"},{"key":"2026010913082171200_ejhf2735-bib-0010","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s13063-019-3474-5","article-title":"Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF)","volume":"20","author":"Jensen","year":"2019","journal-title":"Trials"},{"key":"2026010913082171200_ejhf2735-bib-0011","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.3390\/cells9051175","article-title":"Macrophage activation markers, CD163 and CD206, in acute-on-chronic liver failure","volume":"9","author":"Nielsen","year":"2020","journal-title":"Cell"},{"key":"2026010913082171200_ejhf2735-bib-0012","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/003655102760145852","article-title":"Characterization of an enzyme-linked immunosorbent assay for soluble CD163","volume":"62","author":"M\u00f8ller","year":"2002","journal-title":"Scand J Clin Lab Invest"},{"key":"2026010913082171200_ejhf2735-bib-0013","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1515\/cclm-2013-0451","article-title":"A soluble form of the macrophage-related mannose receptor (MR\/CD206) is present in human serum and elevated in critical illness","volume":"52","author":"R\u00f8dgaard-Hansen","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"2026010913082171200_ejhf2735-bib-0014","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2026010913082171200_ejhf2735-bib-0015","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease","volume":"141","author":"Mazer","year":"2020","journal-title":"Circulation"},{"key":"2026010913082171200_ejhf2735-bib-0016","doi-asserted-by":"crossref","first-page":"e1056","DOI":"10.1210\/clinem\/dgaa057","article-title":"Dapagliflozin suppresses hepcidin and increases erythropoiesis","volume":"105","author":"Ghanim","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026010913082171200_ejhf2735-bib-0017","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009333","article-title":"Effect of empagliflozin on multiple biomarkers in heart failure: insights from the Empire Heart Failure trial","volume":"15","author":"Jensen","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2026010913082171200_ejhf2735-bib-0018","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects","volume":"139","author":"Sano","year":"2019","journal-title":"Circulation"},{"key":"2026010913082171200_ejhf2735-bib-0019","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1111\/dom.14517","article-title":"Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: data from a randomized, placebo-controlled study","volume":"23","author":"Thiele","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2026010913082171200_ejhf2735-bib-0020","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2213-8587(20)30382-X","article-title":"Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial","volume":"9","author":"Jensen","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026010913082171200_ejhf2735-bib-0021","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1161\/CIRCULATIONAHA.120.053463","article-title":"Metabolic effects of empagliflozin in heart failure: a randomized, double-blind, and placebo-controlled trial (Empire HF Metabolic)","volume":"143","author":"Jensen","year":"2021","journal-title":"Circulation"},{"key":"2026010913082171200_ejhf2735-bib-0022","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12933-022-01463-2","article-title":"The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker)","volume":"21","author":"Omar","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"2026010913082171200_ejhf2735-bib-0023","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jacc.2008.04.061","article-title":"Anemia and mortality in heart failure patients: a systematic review and meta-analysis","volume":"52","author":"Groenveld","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026010913082171200_ejhf2735-bib-0024","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.030099","article-title":"Anemia and iron deficiency in heart failure","volume":"138","author":"Anand","year":"2018","journal-title":"Circulation"},{"key":"2026010913082171200_ejhf2735-bib-0025","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1056\/NEJMoa1214865","article-title":"RED-HF Investigators. Treatment of anemia with darbepoetin alfa in systolic heart failure","volume":"368","author":"Swedberg","year":"2013","journal-title":"N Engl J Med"},{"key":"2026010913082171200_ejhf2735-bib-0026","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ahj.2013.01.017","article-title":"Iron deficiency in chronic heart failure: an international pooled analysis","volume":"165","author":"Klip","year":"2013","journal-title":"Am Heart J"},{"key":"2026010913082171200_ejhf2735-bib-0027","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMc1306321","article-title":"Darbepoetin alfa in systolic heart failure","volume":"369","author":"Karakas","year":"2013","journal-title":"N Engl J Med"},{"key":"2026010913082171200_ejhf2735-bib-0028","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ejhf.823","article-title":"Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis","volume":"20","author":"Anker","year":"2018","journal-title":"Eur J Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ejhf.2735","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ejhf.2735","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/2\/226\/65562297\/eurjhf_25_2_226.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/2\/226\/65562297\/eurjhf_25_2_226.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:10:17Z","timestamp":1767982217000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/25\/2\/226\/8341720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,14]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,12,14]]},"published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.2735","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2]]},"published":{"date-parts":[[2022,12,14]]},"assertion":[{"value":"2022-08-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}